The Effects of 8-Week Hydrogen-Rich Water Consumption on Appetite, Body Composition, Sleep Quality, and Circulating Glucagon-like Peptide-1 in Obese Men and Women (HYDRAPPET): A Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Glucagon.

This randomized, placebo-controlled, double-blind trial aimed to evaluate the effects of H2 supplementation on appetite, body composition, sleep quality, obesity-specific quality of life, and related biomarkers in obese men and women.

Why It Was Studied

Background and Objectives: Preliminary studies indicate that dihydrogen (H2) may affect molecular pathways involved in appetite regulation; however, its role in influencing patient-reported appetite outcomes in individuals with obesity remains uncertain.

Who Took Part

The study group was 36 participants.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Glucagon, giving a reference point.

What Was Measured

Background and Objectives: Preliminary studies indicate that dihydrogen (H2) may affect molecular pathways involved in appetite regulation; however, its role in influencing patient-reported appetite outcomes in individuals with obesity remains uncertain.

Topics PubMed links to this paper include Obesity, Appetite, Hydrogen, Body Composition, Sleep Quality, Glucagon-Like Peptide 1 and Quality of Life.

The authors tagged it with the keywords GLP-1, cholesterol, cravings, dihydrogen and supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 36 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Medicina (Kaunas, Lithuania)), a journal based in Switzerland.

More context: the Glucagon compound page, all human trials.